Windtree Therapeutics Leverages Heart Failure Asset Istaroxime in Multiple Indications

Published on : Published by : Alex Keown

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders. Despite cardiovascular disease being the number-one cause of global death, Fraser said few companies are pouring their resources into addressing the disease, especially when compared to oncology research. Windtree’s lead clinical program istaroxime is a novel therapeutic aimed at heart failure, the number one reason for hospitalization in the United States.

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

Published on : Published by : BioBuzz Media

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.

DrugViu to Relocate and Expand Operations in Northern Virginia

Published on : Published by : Alex Keown

Launched in New York, two-year-old data science company DrugViu, which has created a comprehensive and diverse Real-World Evidence Platform for immunological research, will relocate its headquarters to Northern Virginia.

Jeeva Informatics Hosts Rare Disease Panel on Decentralized, Patient-Focused Clinical Trials

Published on : Published by : Steven Surdez

In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

Published on : Published by : BioBuzz Media

Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.